| __timestamp | BeiGene, Ltd. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 94231000 |
| Thursday, January 1, 2015 | 58250000000 | 146394000 |
| Friday, January 1, 2016 | 98033000 | 188272000 |
| Sunday, January 1, 2017 | 269018000 | 166707000 |
| Monday, January 1, 2018 | 679005000 | 401843000 |
| Tuesday, January 1, 2019 | 927338000 | 560909000 |
| Wednesday, January 1, 2020 | 1294877000 | 722343000 |
| Friday, January 1, 2021 | 1459239000 | 771182000 |
| Saturday, January 1, 2022 | 1640508000 | 877090000 |
| Sunday, January 1, 2023 | 1778594000 | 877387000 |
Unleashing the power of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, BeiGene, Ltd. has demonstrated a robust strategic focus on R&D, with expenditures increasing by approximately 8,000% from 2014 to 2023. This surge underscores BeiGene's aggressive pursuit of groundbreaking therapies. In contrast, Sarepta Therapeutics, Inc. has maintained a steady yet modest growth in R&D spending, with a 9-fold increase over the same period. This reflects a more measured approach to innovation. The data highlights a stark contrast in strategic priorities, with BeiGene's R&D spending in 2023 nearly double that of Sarepta's. As the biotech industry continues to evolve, these spending patterns may offer insights into future market leadership and therapeutic breakthroughs.
Vertex Pharmaceuticals Incorporated vs BeiGene, Ltd.: Strategic Focus on R&D Spending
Comparing Innovation Spending: GSK plc and BeiGene, Ltd.
Who Prioritizes Innovation? R&D Spending Compared for BeiGene, Ltd. and Insmed Incorporated
Annual Revenue Comparison: BeiGene, Ltd. vs Sarepta Therapeutics, Inc.
Research and Development: Comparing Key Metrics for BeiGene, Ltd. and Madrigal Pharmaceuticals, Inc.
Research and Development Investment: BeiGene, Ltd. vs Halozyme Therapeutics, Inc.
R&D Spending Showdown: BeiGene, Ltd. vs Opthea Limited
Research and Development Expenses Breakdown: BeiGene, Ltd. vs ImmunityBio, Inc.
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.
Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Mesoblast Limited